Dextrose Monohydrate 50% Inj · 308 days since initial FDA posting
FDA lists Dextrose Monohydrate 50% Inj as To Be Discontinued (Hospira, Inc., a Pfizer Company).
No availability text on this FDA row.
Dextrose Monohydrate 50% Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Dextrose Monohydrate 50% Injection
- Manufacturer
- Hospira, Inc., a Pfizer Company
- Dosage Form
- Injection
- Presentation
- Dextrose Monohydrate 50%, Injection, 50% Dextrose Injection 0.5 g/mL; ABBOJECT® Glass Syringe (NDC 0409-4902-34)
- Package NDC
- 0409-4902-34
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Nov 7, 2025
- Last Updated
- Nov 7, 2025
- Therapeutic Category
- Endocrinology/Metabolism, Gastroenterology, Pediatric
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Nearby, Other Dextrose Shortage Records
Dextrose Monohydrate 10% Injection
B. Braun Medical Inc.
Injection
Dextrose Monohydrate 5% Injection
B. Braun Medical Inc.
Injection
Dextrose Monohydrate 5% Injection
B. Braun Medical Inc.
Injection
Dextrose Monohydrate 10% Injection
B. Braun Medical Inc.
Injection
Dextrose Monohydrate 5% Injection
B. Braun Medical Inc.
Injection
Dextrose Monohydrate 10% Injection
B. Braun Medical Inc.
Injection
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.